ClinicalTrials.gg
CompletedNCT06679413Updated Jul 2, 2026Results posted

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

A Phase 1 interventional study of midazolam and metformin in Healthy Study Participants, sponsored by UCB BIOSCIENCES, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to assess the single-dose pharmacokinetics (PK) of 3 probe drugs (midazolam, bupropion, and metformin) before and after repeat doses of ZX008

02

Conditions studied

  • Healthy Study Participants

Keywords

  • Healthy Study Participants
  • fenfluramine HCl
  • Drug-drug interaction
  • Phase 1
  • ZX008
03

In context

Lead sponsor

UCB BIOSCIENCES, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 55 years of age inclusive at the time of signing the form (ICF)
  • Body weight of at least 50 kg and within the range 18 to 32 kg/m\^2 (inclusive)
  • Male or female
  • Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) above 1.1x (ULN)
  • >ULN (isolated bilirubin \<1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
  • Participant has current or past history of cardiovascular or cerebrovascular disease, such as valvular heart disease, and/or pulmonary hypertension. Participants with any history of stroke or myocardial infarction are excluded.
  • Clinically significant history or presence of (ECG) or echocardiogram (ECHO) findings as judged by the investigator or designee at the Screening Visit and Check-in, including each criterion listed below:
  • Abnormal sinus rhythm (heart rate outside of 40bpm and 100bpm)
  • (QT interval corrected using Fridericia's formula) interval >450 msec for male participants or >470 msec for female participants (QTcF is the QT interval corrected for heart rate according to Fridericia's formula, it can be either machine read or manually overread)
  • QRS interval >120 msec, confirmed by manual over read
  • PR interval >220 msec
  • Greater than trace aortic valve regurgitation
  • Greater than trace mitral valve regurgitation
  • Possible signs of pulmonary arterial hypertension (PAH) with abnormal pulmonary artery systolic pressure (PASP) or PASP >35 mmHg
  • Evidence of left ventricular dysfunction (systolic or diastolic)
  • Clinically significant structural cardiac abnormality, including, but not limited to, mitral valve prolapse, atrial or ventricular septal defects, and patent ductus arteriosus with reversal of shunt (right to left shunt). Note: Patent foramen ovale or a bicuspid aortic valve is not considered exclusionary
  • Clinically significant abnormal blood pressure (as determined by the investigator)
  • Participant has a current or past history of glaucoma
  • Participant has used hepatic enzyme-inducing drugs (eg, , phenobarbital, isoniazid, phenytoin, rifampicin) within 30 days before the first administration of the cocktail of 3 probe drugs (metformin, midazolam, bupropion) and through the day of discharge from the site
  • Participant has used other prescription drugs, including vaccinations, over-the-counter medications, herbal/traditional medicines, or dietary supplements within 14 days before the first administration of the cocktail of probe drugs (excluding medicines for external use), with the exception of acetaminophen (up to 2 g/day)
  • Consent to genotyping is required for participation in the study. Poor metabolizers of CYP (cytochrome P450) 3A4 or CYP2B6 based on genotyping and as categorized by the testing laboratory will be excluded from the study
  • Positive test for alcohol and/or prohibited concomitant drugs (including cotinine) at Screening Visit and on Day -1
  • Participant has donated blood or plasma or has experienced blood loss ≥500 mL within 90 days, ≥200 mL within 30 days, or has donated any blood or plasma within 14 days before first administration of study treatments
  • Any consumption of food products with a known Drug-drug interaction (DDI) impact (eg, grapefruit, grapefruit juice, Seville oranges, or products containing them) for at least 1 week before Day 1 and through day of discharge from the site
  • Consumption of more than 600 mg of caffeine/day (1 cup of coffee contains approximately 100 mg of caffeine, 1 cup of tea approximately 30 mg, and 1 glass of cola approximately 20 mg) within 30 days before Day 1 and through day of discharge from the site
  • Participant is a current smoker or has used nicotine-containing products (eg, tobacco, patches, gum, vapes, or e-cigarettes) within 35 days before Day 1 and through day of discharge from the site
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Study participants will receive a single dose of the cocktail of probe drugs at pre-specified timepoints followed by a wash out period. The same study participants will then receive repeated oral doses of fenfluramine HCl (ZX008) and a single dose of the cocktail of probe drugs at pre-specified time points during this Treatment Period.

    Drug: midazolam · Drug: metformin · Drug: bupropion · Drug: fenfluramine HCl

Interventions

  • Drugmidazolam

    Study participants will receive a pre specified single oral dose of probe drug midazolam on Day 1 and Day 22 of the study

  • Drugmetformin

    Study participants will receive a pre-specified single oral dose of probe drug metformin on Day 1 and Day 22 of the study

  • Drugbupropion

    Study participants will receive a pre-specified single oral dose of probe drug bupropion on Day 1 and Day 22 of the study

  • Study participants will receive pre-specified repeated oral doses of fenfluramine HCl (ZX008) from Day 6 to 26 during the study

    Also known as: Fintepla, ZX0008

06

What researchers measure

Primary outcomes

  1. Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State

    Cmax is the maximum observed plasma concentration of Midazolam alone and in combination with ZX008 at steady state.

    Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose

  2. Maximum Concentration (Cmax) of Metformin Alone and in Combination With ZX008 at Steady State

    Cmax is the maximum observed plasma concentration of Metformin alone and in combination with ZX008 at steady state.

    Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose

  3. Maximum Concentration (Cmax) of Bupropion Alone and in Combination With ZX008 at Steady State

    Cmax is the maximum observed plasma concentration of Bupropion alone and in combination with ZX008 at steady state.

    Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose

  4. Area Under the Curve From 0 to Infinity (AUC) of Midazolam Alone and in Combination With ZX008 at Steady State

    AUC is area under the plasma concentration-time curve from time 0 to infinity of Midazolam alone and in combination with ZX008 at steady state.

    Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose

  5. Area Under the Curve From 0 to Infinity (AUC) of Metformin Alone and in Combination With ZX008 at Steady State

    AUC is area under the plasma concentration-time curve from time 0 to infinity of Metformin alone and in combination with ZX008 at steady state.

    Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose

  6. Area Under the Curve From 0 to Infinity (AUC) of Bupropion Alone and in Combination With ZX008 at Steady State

    AUC is area under the plasma concentration-time curve from time 0 to infinity of Bupropion alone and in combination with ZX008 at steady state.

    Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose

  7. Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Midazolam Alone and in Combination With ZX008 at Steady State

    AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Midazolam alone and in combination with ZX008 at steady state.

    Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose

  8. Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Metformin Alone and in Combination With ZX008 at Steady State

    AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Metformin alone and in combination with ZX008 at steady state.

    Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose

  9. Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Bupropion Alone and in Combination With ZX008 at Steady State

    AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Bupropion alone and in combination with ZX008 at steady state.

    Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose

Secondary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A treatment-emergent adverse events was defined as any AE with a start date and time on or after the first dose of any study drug or any unresolved event already present before treatment administration that worsens infrequency or intensity following exposure to any of the study drugs. The percentage of participants data was rounded to one decimal place. SFU: Safety Follow-Up.

    Time frame: From Baseline (Day 1) to the End of Safety Follow-Up (up to 116 days)

07

Results

Posted Jul 2, 2026

Participant flow

The study started to enroll participants in December 2024 and concluded in June 2025.

Treatment Period 1: Days 1 - 5
Participant flow — Treatment Period 1: Days 1 - 5
Milestone3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period)
Started220
Completed220
Not completed00
Treatment Period 2: Days 6 - 26
Participant flow — Treatment Period 2: Days 6 - 26
Milestone3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period)
Started022
Completed022
Not completed00

Outcome measures

PrimaryMaximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State

Cmax is the maximum observed plasma concentration of Midazolam alone and in combination with ZX008 at steady state.

Time frame:
Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State
nanograms per milliliter (ng/mL)3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2)
Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State10.44 ± 31.68.203 ± 40.6
Statistical analysis
  • 3-probe Drug Cocktail Alone (Treatment Period 1) vs ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) · Geometric least square mean (glsm) ratio: 0.7854 · 90% CI 0.6893 to 0.8949
PrimaryMaximum Concentration (Cmax) of Metformin Alone and in Combination With ZX008 at Steady State

Cmax is the maximum observed plasma concentration of Metformin alone and in combination with ZX008 at steady state.

Time frame:
Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of Metformin Alone and in Combination With ZX008 at Steady State
ng/mL3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2)
Maximum Concentration (Cmax) of Metformin Alone and in Combination With ZX008 at Steady State943.6 ± 17.4959.8 ± 26.0
Statistical analysis
  • 3-probe Drug Cocktail Alone (Treatment Period 1) vs ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) · Glsm ratio: 1.0171 · 90% CI 0.9337 to 1.1080
PrimaryMaximum Concentration (Cmax) of Bupropion Alone and in Combination With ZX008 at Steady State

Cmax is the maximum observed plasma concentration of Bupropion alone and in combination with ZX008 at steady state.

Time frame:
Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of Bupropion Alone and in Combination With ZX008 at Steady State
ng/mL3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2)
Maximum Concentration (Cmax) of Bupropion Alone and in Combination With ZX008 at Steady State76.11 ± 39.668.50 ± 39.1
Statistical analysis
  • 3-probe Drug Cocktail Alone (Treatment Period 1) vs ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) · Glsm ratio: 0.9000 · 90% CI 0.7851 to 1.0317
PrimaryArea Under the Curve From 0 to Infinity (AUC) of Midazolam Alone and in Combination With ZX008 at Steady State

AUC is area under the plasma concentration-time curve from time 0 to infinity of Midazolam alone and in combination with ZX008 at steady state.

Time frame:
Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Reported as:
Geometric mean · hour*nanograms per milliliter (hr*ng/mL)
Area Under the Curve From 0 to Infinity (AUC) of Midazolam Alone and in Combination With ZX008 at Steady State
hour*nanograms per milliliter (hr*ng/mL)3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2)
Area Under the Curve From 0 to Infinity (AUC) of Midazolam Alone and in Combination With ZX008 at Steady State24.84 ± 46.219.08 ± 47.5
Statistical analysis
  • 3-probe Drug Cocktail Alone (Treatment Period 1) vs ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) · Glsm ratio: 0.7681 · 90% CI 0.7053 to 0.8366
PrimaryArea Under the Curve From 0 to Infinity (AUC) of Metformin Alone and in Combination With ZX008 at Steady State

AUC is area under the plasma concentration-time curve from time 0 to infinity of Metformin alone and in combination with ZX008 at steady state.

Time frame:
Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Reported as:
Geometric mean · hr*ng/mL
Area Under the Curve From 0 to Infinity (AUC) of Metformin Alone and in Combination With ZX008 at Steady State
hr*ng/mL3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2)
Area Under the Curve From 0 to Infinity (AUC) of Metformin Alone and in Combination With ZX008 at Steady State6381 ± 22.06482 ± 23.9
Statistical analysis
  • 3-probe Drug Cocktail Alone (Treatment Period 1) vs ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) · Glsm ratio: 1.0102 · 90% CI 0.9117 to 1.1194
PrimaryArea Under the Curve From 0 to Infinity (AUC) of Bupropion Alone and in Combination With ZX008 at Steady State

AUC is area under the plasma concentration-time curve from time 0 to infinity of Bupropion alone and in combination with ZX008 at steady state.

Time frame:
Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Reported as:
Geometric mean · hr*ng/mL
Area Under the Curve From 0 to Infinity (AUC) of Bupropion Alone and in Combination With ZX008 at Steady State
hr*ng/mL3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2)
Area Under the Curve From 0 to Infinity (AUC) of Bupropion Alone and in Combination With ZX008 at Steady State407.7 ± 27.0378.0 ± 33.0
Statistical analysis
  • 3-probe Drug Cocktail Alone (Treatment Period 1) vs ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) · Glsm ratio: 0.9614 · 90% CI 0.8653 to 1.0681
PrimaryArea Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Midazolam Alone and in Combination With ZX008 at Steady State

AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Midazolam alone and in combination with ZX008 at steady state.

Time frame:
Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Reported as:
Geometric mean · hr*ng/mL
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Midazolam Alone and in Combination With ZX008 at Steady State
hr*ng/mL3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2)
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Midazolam Alone and in Combination With ZX008 at Steady State24.09 ± 47.118.40 ± 49.0
Statistical analysis
  • 3-probe Drug Cocktail Alone (Treatment Period 1) vs ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) · Glsm ratio: 0.7636 · 90% CI 0.6981 to 0.8352
PrimaryArea Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Metformin Alone and in Combination With ZX008 at Steady State

AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Metformin alone and in combination with ZX008 at steady state.

Time frame:
Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Reported as:
Geometric mean · hr*ng/mL
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Metformin Alone and in Combination With ZX008 at Steady State
hr*ng/mL3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2)
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Metformin Alone and in Combination With ZX008 at Steady State6365 ± 21.46448 ± 23.3
Statistical analysis
  • 3-probe Drug Cocktail Alone (Treatment Period 1) vs ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) · Glsm ratio: 1.0130 · 90% CI 0.9281 to 1.1057
PrimaryArea Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Bupropion Alone and in Combination With ZX008 at Steady State

AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Bupropion alone and in combination with ZX008 at steady state.

Time frame:
Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Reported as:
Geometric mean · hr*ng/mL
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Bupropion Alone and in Combination With ZX008 at Steady State
hr*ng/mL3-probe Drug Cocktail Alone (Treatment Period 1)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2)
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Bupropion Alone and in Combination With ZX008 at Steady State344.8 ± 40.0351.0 ± 33.6
Statistical analysis
  • 3-probe Drug Cocktail Alone (Treatment Period 1) vs ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) · Glsm ratio: 1.0182 · 90% CI 0.9174 to 1.1299
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A treatment-emergent adverse events was defined as any AE with a start date and time on or after the first dose of any study drug or any unresolved event already present before treatment administration that worsens infrequency or intensity following exposure to any of the study drugs. The percentage of participants data was rounded to one decimal place. SFU: Safety Follow-Up.

Time frame:
From Baseline (Day 1) to the End of Safety Follow-Up (up to 116 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participants3-probe Drug Cocktail Alone (Treatment Period 1: D1-D5)ZX008 15 mg BID Alone (Treatment Period 2: D6-D21)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2: D22-SFU)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)13.650.022.7

Adverse events

Collected over From Baseline (Day 1) to the End of Safety Follow-Up (up to 116 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3-probe Drug Cocktail Alone (Treatment Period 1: D1-D5)0/22 (0%)0/22 (0%)1/22 (4.5%)
ZX008 15 mg BID Alone (Treatment Period 2: D6-D21)0/22 (0%)0/22 (0%)7/22 (31.8%)
ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2: D22-SFU)0/22 (0%)0/22 (0%)2/22 (9.1%)
Most frequent other events
Most frequent other events
Event3-probe Drug Cocktail Alone (Treatment Period 1: D1-D5)ZX008 15 mg BID Alone (Treatment Period 2: D6-D21)ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2: D22-SFU)
FatigueGeneral disorders0/224/220/22
HeadacheNervous system disorders0/223/220/22
DiarrhoeaGastrointestinal disorders1/220/222/22

Baseline characteristics

Baseline Characteristics refer to the Safety Set which consisted of all study participants who had received at least 1 dose of any of the study treatments.

Age, Continuous
Age, Continuous(years)All Treated Participants
Mean37.4 ± 8.5
Age, Customized
Age, Customized(Participants)All Treated Participants
18 - <65 years22
65 - <85 years0
>= 85 years0
Sex: Female, Male
Sex: Female, Male(Participants)All Treated Participants
Female10
Male12
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Treated Participants
Asian1
Black or African American13
White8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Treated Participants
Hispanic or Latino9
Not Hispanic or Latino13
08

Study locations

1 site
  • Up0132 1001
    Baltimore, Maryland 21225, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Jun 2025, 6 months.

Results were first posted in Jul 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 7, 2024
StartActual
Dec 4, 2024
Primary completionActual
Jun 12, 2025
CompletionActual
Jun 12, 2025
Results first posted
Jul 2, 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06679413
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Dec 4, 2024
Primary completion
Jun 12, 2025
Completion
Jun 12, 2025
Results posted
Jul 2, 2026
Last update
Jul 2, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenfluramine

Start the discussion